Multivariate analysis of progression
Variables . | RR of progression (95% CI) . | P . |
|---|---|---|
| Disease type and use of TBI | .002† | |
| NHL with TBI, n = 37 | 1.00 | - |
| NHL no TBI, n = 42 | 3.02 (1.71-5.32) | < .001 |
| HL with TBI, n = 8* | 2.18 (0.86-5.52) | .10 |
| HL no TBI, n = 27 | 2.15 (1.14-4.05) | .02 |
| Disease status before second transplantation | < .001† | |
| Complete remission, n = 24 | 1.00 | - |
| Relapse/primary induction failure, chemosensitive, n = 39 | 1.38 (0.77-2.46) | .28 |
| Relapse/primary induction failure, chemoresistant, n = 23 | 2.90 (1.38-6.08) | .005 |
| Relapse/primary induction failure, untreated, n = 28 | 3.45 (1.74-6.87) | < .001 |
Variables . | RR of progression (95% CI) . | P . |
|---|---|---|
| Disease type and use of TBI | .002† | |
| NHL with TBI, n = 37 | 1.00 | - |
| NHL no TBI, n = 42 | 3.02 (1.71-5.32) | < .001 |
| HL with TBI, n = 8* | 2.18 (0.86-5.52) | .10 |
| HL no TBI, n = 27 | 2.15 (1.14-4.05) | .02 |
| Disease status before second transplantation | < .001† | |
| Complete remission, n = 24 | 1.00 | - |
| Relapse/primary induction failure, chemosensitive, n = 39 | 1.38 (0.77-2.46) | .28 |
| Relapse/primary induction failure, chemoresistant, n = 23 | 2.90 (1.38-6.08) | .005 |
| Relapse/primary induction failure, untreated, n = 28 | 3.45 (1.74-6.87) | < .001 |